EMD Serono

223 articles with EMD Serono

• EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

  3/31/2022

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced 13 abstracts from the Company’s multiple sclerosis portfolio will be presented at the 2022 American Academy of Neurology Annual Meeting, being held April 2-7.

• New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favorable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

  2/24/2022

  EMD Serono announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® tablets had more favorable relapse outcomes and longer time to switch to another disease modifying therapy compared to the oral DMTs fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.

• Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

  2/18/2022

  Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO ® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma.

• European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

  2/18/2022

  EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib).

• EMD Serono Launches New Sustainable Slim Pack for Fertility Medication

  2/17/2022

  EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size for convenience and environmental impact.

• EMD Serono Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

  12/20/2021

  Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

• TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

  12/17/2021

  TEPMETKO ® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with MET ex14 Skipping Alterations.

• EMD Serono Launches New Fertility LifeLines™ Portal to Increase Support and Access for Patients Impacted by Infertility

  11/29/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its enhanced Fertility LifeLines™ patient support program, based on input from reproductive health medical professionals and patients on their fertility journey.

• New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

  10/14/2021

  EMD Serono today shared data in an oral presentation from a Phase II post-hoc analysis

• New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

  10/13/2021

  New Real-World MAVENCLAD ® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

• EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

  10/4/2021

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced enrollment has been completed in the Phase III EVOLUTION RMS clinical trial program, which is evaluating the efficacy and safety of investigational Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis.

• EMD Serono to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

  9/12/2021

  EMD Serono announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year’s World Conference on Lung Cancer, September 8-14, 2021, and the European Society for Medical Oncology Congress, September 16-21, 2021.

• Data from EMD Serono’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21

  5/19/2021

  New analyses from pivotal BAVENCIO® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma

• EMD Serono Announces New Data Strengthening Evidence for Use of MAVENCLAD During the COVID-19 Pandemic

  4/28/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets,

• EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

  4/23/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets, which may contribute to their ability to fight infections and develop protective antibodies from vaccines.

• Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS

  4/16/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis.

• EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

  4/12/2021

  US National Cancer Institute led Phase II clinical study met its primary objective with 36% confirmed ORR, and showed durable responses 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer

• New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines

  2/25/2021

   EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine) tablets in patients with relapsing multiple sclerosis (RMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021

• Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity

  2/9/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, presented retrospective HIV-associated wasting (HIVAW) prevalence and comorbidity data today from a claims database analysis at the Miami Center for AIDS Research (CFAR) Conference on HIV and Aging in the Era of ART and COVID-19

• FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

  2/3/2021

  - TEPMETKO is approved for both treatment naïve and previously treated METex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treated METex14 patients in the VISION study - VISION is the largest clinical study to date of patients with metastatic NSCLC with MET exon 14 skipping alterations